SELLAS Life Sciences Group, Inc. Tax Withholding Paid on Stock Awards
SELLAS Life Sciences Group, Inc. (SLS) reported Tax Withholding Paid on Stock Awards of $527.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-03-19
- SELLAS Life Sciences Group, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $527.00K, a 723.44% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $64.00K, a 106.45% increase from fiscal 2023.
- SELLAS Life Sciences Group, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $31.00K.
- SELLAS Life Sciences Group, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|
| 2025-12-31 | $527.00K 10-K · filed 2026-03-19 |
| 2024-12-31 | $64.00K 10-K · filed 2026-03-19 |
| 2023-12-31 | $31.00K 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |